Skip to main content
PMC home page
Scientific Reports logoLink to Scientific Reports
. 2016 Aug 11;6:31485. doi: 10.1038/srep31485

The Associations of HLA-A*02:01 and DRB1*11:01 with Hepatitis C Virus Spontaneous Clearance Are Independent of IL28B in the Chinese Population

Jieting Huang 1,2,*, Ke Huang 1,2,*, Ru Xu 1,2,*, Min Wang 1,2, Qiao Liao 1,2, Huaping Xiong 1,2, Chengyao Li 3, Xi Tang 3, Zhengang Shan 1,2, Ming Zhang 4, Xia Rong 1,2,a, Kenrad Nelson 5, Yongshui Fu 1,2,b
PMCID: PMC4980596  PMID: 27511600

Abstract

Spontaneous clearance of hepatitis C virus (HCV) occurs in 10–40% of the infections. Specific human leukocyte antigen (HLA) alleles have been identified in associating with HCV clearance. However, data on the association of HLA with the spontaneous clearance of HCV are scarce in the Chinese population. In the current study we studied the HLA class I and class II genes in 231 Chinese voluntary blood donors who had cleared HCV infection spontaneously compared to 429 subjects with chronic HCV infections. We also studied their IL28B SNP (rs8099917) genotype, since a number of investigators have found a strong association of IL28B with spontaneous or treatment induced HCV clearance. We found that HLA-A*02:01 and DQB1*05:02 distributed differently between the two groups after Bonferroni correction (odds ratio [OR] = 1.839, Pc = 0.024 and OR = 0.547, Pc = 0.016, respectively). Multivariate logistic regression analysis suggested that A*02:01 and DRB1*11:01 (OR = 1.798, P = 0.008 and OR = 1.921, P = 0.005, respectively) were associated with HCV spontaneous clearance, independent of age, gender and IL28B polymorphism. We concluded that in the Chinese population, HLA-A*02:01 and DRB1*11:01 might be associated with the host capacity to clear HCV independent of IL28B, which suggesting that the innate and adaptive immune responses both play an important role in the control of HCV.

Globally, hepatitis C virus (HCV) infection contributes significantly to chronic liver diseases, including liver fibrosis, cirrhosis, hepatocellular carcinoma or liver failure1. An estimated of 170–210 million people worldwide are HCV seropositive2, and the HCV incidence in China was over 200,000 infections per year from 2012 to 20153.

The spontaneous clearance of HCV occurs in 10–40% of the infections worldwide4. The mechanisms of HCV clearance are not well elucidated. Clearance of HCV has been associated with several demographic and host factors, including female gender, younger age, Caucasian or Hispanic ethnicity, co-infection with hepatitis B virus (HBV) and host immunity5,6,7. Evidence that host genetic constitution was associated with HCV clearance was obtained from studies of single nucleotide polymorphisms (SNPs) linked to the interferon lambda 3 (IFNL3) gene8,9. The IFNL3 gene, also known as interleukin-28B (IL28B), encodes an innate interferon IFNλ3, which has antiviral activity upon the activation of the JAK-STAT pathway that up-regulates the expression of interferon-stimulated genes (ISGs)10. Although the underlying mechanism for this effect is not well understood, the association of IL28B SNPs with HCV spontaneous and treatment induced clearance is clearly defined8,9,11, which has prompted the usage of IL28B SNPs in designing the HCV therapy strategy and to predict treatment outcome12.

The IL28B polymorphism has also been used to predict the probability of HCV spontaneous clearance11,13. However, the combination of IL28B SNPs with HLA-DQB1*03:01 predicted only about 15% of the HCV spontaneous clearance cases in subjects of European and African ancestry11. In addition, a racial difference was associated with the frequency of HCV spontaneous clearance and that was unexplained by the difference of IL28B polymorphisms in diverse populations. For example, Caucasians and Hispanics were predicted to have 3–4 times higher HCV clearance proportion than those of the African ancestry6,14,15, while the frequency of IL28B rs12979860-C allele, which was in favor of HCV clearance, was 55–65% in the European and American subjects, compared with 30–40% in the African population8. Additionally, the frequency of rs12979860-C allele was over 90% in the Chinese population8,16, however only 20% of HCV infected subjects spontaneously cleared their HCV infection17, which was lower than that of Caucasians. HCV clearance can be partially explained by the distribution of IL28B SNPs, however other factors are involved.

Cellular immune responses mediated by activated CD4+ and CD8+ T cells are critical for HCV clearance18,19. Strong and broad CD4+ helper and CD8+ effector T cell responses are associated with HCV clearance20,21; progression to chronicity has been associated with the functional exhaustion of HCV-specific CD4+ and CD8+ T cells22. The activation of T cells is determined by the recognition of T cell receptors and the human leukocyte antigen (HLA) presented on the surface of the infected hepatocytes20. Previous studies have identified specific HLA class I alleles associated with HCV clearance, such as HLA-A*03, B*27, B*57, Cw*01 and Cw*0413,23,24,25. HLA class II genes, including DRB1*11:01 and DQB1*03:01, have been associated with HCV clearance, while DRB1*03:01 and DQB1*02:01 have been associated with persistent HCV infection24,26. It should be noted that the association of HLA and HCV spontaneous clearance seems to be race specific26,27. Thio et al. identified HLA-DQB1*03:01 to associate with HCV clearance in black but not white subjects, while the association of DRB1*01:01 and DRB1*03:01 was associated with HCV clearance in white but not black subjects26. Wang et al. reported opposite associations of HLA-A*02 and DRB1*12 with resolution of HCV infection between Caucasians and non-Caucasians27. However, there is little information on the association of specific HLA alleles with the spontaneous clearance of HCV in the Chinese population, despite the fact that the HCV prevalence is high in China. In addition, only a few studies have studied the combined association of the IL28B genotypes and HLA alleles with HCV clearance13.

In this study, we aimed to identify specific HLA class I (A, B and C) and class II alleles (DPB1, DQB1 and DRB1) associated with HCV spontaneous clearance among the 231 blood donors with HCV spontaneous clearance and 429 donors with persistent infections. In comparison, part of the genotyping information for HLA-A, B and DRB1 genes in the persistent infection donors were included from our previous report28. As far as we are aware, this study is the first to report the combined association of IL28B and HLA alleles with the spontaneous clearance of HCV in a large Chinese population.

Results

Epidemiological characteristics of the study subjects

A total of 1493 HCV seropositive voluntary blood donors were identified and recruited during July 2009 through March 2015. Among them, 231 donors who were anti-HCV positive but HCV RNA negative represented the spontaneous clearance group, while 1262 subjects with both anti-HCV and HCV RNA positive represented the persistent infection group. The overall spontaneous clearance rate was 15.5%, and male donors showed significant lower clearance rate than female donors (12.7% vs. 26.8%, P = 2.03E-9 in Chi-square test, Table S1). In order to assess the association of HLA alleles and HCV clearance, all the subjects with HCV clearance (n = 231) were enrolled, while 429 out of 1262 subjects represented the persistent infection group were sampled using systematic random sampling method. As shown in Table 1, all the study subjects were Chinese and most were of Han ethnicity. 34.2% (79/231) of the donors who spontaneously cleared the virus were female, compared with 17.2% (74/429) in those with persistent infection. The male/female ratio was significantly lower in the spontaneous clearance group (P = 8.58E-7 in Chi-square test). Additionally, the subjects in the clearance group were significantly younger than those in the persistent infection group (P = 3.29E-4 in T-test).

Table 1. Characteristics of the blood donors with cleared and persistent HCV infection.

Characteristic Donors with HCV infection
 P
Spontaneous clearance (n = 231) Persistent infection (n = 429)
Age Median (Range) 24 (18–53) 31 (18–55) 3.29E-4
Gender
 Male n(%) 152 (65.8) 355 (82.8) 8.58E-7
 Female n(%) 79 (34.2) 74 (17.2)
Ethnicity
 Chinese Han n(%) 227 (98.3) 428 (99.8) 0.053
 Chinese others n(%) 4 (1.7) 1 (0.2)
Open in a new tab

Association of HLA class I and class II alleles with HCV spontaneous clearance

First, we determined the frequency of HLA class I and class II alleles in both HCV spontaneous clearance and persistent infection groups. Reliable genotyping for HLA-A, B and DRB1 loci was obtained for all 660 blood donors, while three cases, six cases and one case could not be typed for the C, DPB1 and DQB1 loci, respectively (Table S2). The HLA genotyping identified 13, 21, 13, 12, 13 and 19 specific alleles (frequency >1%) for HLA-A, B, C, DPB1, DQB1 and DRB1 loci, respectively (Figures S1–S6). When assessing the association of HLA with HCV clearance, we focused on the alleles with >5% frequency, because low-frequency alleles were more prone to spurious associations in an exploratory analysis. One allele in HLA class I loci (Table 2) and five in class II loci (Table 3) were found to be distributed differently between the spontaneous clearance group and the persistent infection group. HLA-A*02:01 (odds ratio [OR] = 1.839, 95% confidence interval [CI] = 1.212–2.791, P = 0.004), DQB1*03:01 (OR = 1.398, 95% CI = 1.060–1.843, P = 0.017) and DRB1*11:01 (OR = 1.820, 95% CI = 1.172–2.826, P = 0.007) were more prevalent in donors who cleared HCV. In contrast, DQB1*05:02 (OR = 0.547, 95% CI = 0.370–0.809, P = 0.002), DRB1*04:05 (OR = 0.514, 95% CI = 0.288–0.916, P = 0.022) and DRB1*15:01 (OR = 0.657, 95% CI = 0.448–0.964, P = 0.031) were more frequently found in subjects who had developed a persistent infection. After the Bonferroni correction for multiple comparisons, HLA-A*02:01 (Pc = 0.024) and DQB1*05:02 (Pc = 0.016) were found to be significantly associated with the spontaneous clearance of HCV. It should be noted that although the association of HLA-B*57 and HCV clearance has been widely reported23,25,29,30, the frequency of B*57 was very low (0.4% and 0.6% in the clearance and persistence group, respectively, data not shown) and the association of B*57 and HCV clearance was not significant in our study subjects (P = 0.999, data not shown).

Table 2. Allelic distribution of HLA class I alleles and their correlation with HCV infection outcome in Chinese population.

HLA allele Spontaneous clearance n (%) Persistent infection n (%) P (Pc) OR (95%C.I.)
A*02:01 47 (10.2) 52 (6.1) 0.004 (0.024) 1.839 (1.212, 2.791)
A*02:03 33 (7.1) 65 (7.6) 0.888 0.969 (0.624, 1.504)
A*02:07 54 (11.7) 101 (11.8) 0.883 1.027 (0.718, 1.470)
A*11:01 122 (26.4) 251 (29.3) 0.414 0.895(0.684, 1.169)
A*24:02 53 (11.5) 131 (15.3) 0.083 0.735 (0.519, 1.042)
A*33:03 51 (11.0) 89 (10.4) 0.572 1.113 (0.768, 1.612)
B*13:01 38 (8.2) 67 (7.8) 0.581 1.129 (0.734, 1.737)
B*15:02 39 (8.4) 64 (7.5) 0.351 1.227 (0.797, 1.889)
B*40:01 55 (11.9) 137 (16.0) 0.077 0.724 (0.506, 1.036)
B*46:01 72 (15.6) 134 (15.6) 0.689 1.072 (0.764, 1.504)
B*58:01 44 (9.5) 83 (9.7) 0.832 1.045 (0.699, 1.562)
C*01:02 87 (18.9) 173 (20.3) 0.783 0.959 (0.710, 1.295)
C*03:02 43 (9.3) 80 (9.4) 0.84 1.042 (0.700, 1.549)
C*03:04 59 (12.8) 110 (12.9) 0.819 1.041 (0.735, 1.475)
C*06:02 29 (6.3) 42 (4.9) 0.217 1.363 (0.832, 2.231)
C*07:02 61 (13.3) 151 (17.7) 0.062 0.729 (0.523, 1.017)
C*08:01 54 (11.7) 86 (10.1) 0.234 1.251 (0.865, 1.811)
Open in a new tab

Alleles with >5% frequencies are shown at the 4-digit level and analyzed; Pc, Corrected P value for multiple comparisons by Bonferroni correction. Alleles with statistical significance after Bonferroni correction are indicated in bold.

Table 3. Allelic distribution of HLA class II alleles and their correlation with HCV infection outcome in Chinese population.

HLA allele Spontaneous clearance n (%) Persistent infection n (%) P (Pc) OR (95%C.I.)
DPB1*02:01 73 (16.1) 145 (17.0) 0.914 0.983 (0.716, 1.349)
DPB1*02:02 24 (5.3) 52 (6.1) 0.671 0.897 (0.543, 1.482)
DPB1*04:01 39 (8.6) 70 (8.2) 0.643 1.103 (0.728, 1.671)
DPB1*05:01 178 (39.2) 340 (39.8) 0.695 1.053 (0.812, 1.367)
DPB1*13:01 29 (6.4) 65 (7.6) 0.527 0.862 (0.545, 1.364)
DQB1*02:01 31 (6.7) 60 (7.0) 0.651 0.901 (0.573, 1.417)
DQB1*02:02 33 (7.2) 38 (4.4) 0.063 1.576 (0.972, 2.557)
DQB1*03:01 121 (26.3) 167 (19.5) 0.017 (0.136) 1.398 (1.060, 1.843)
DQB1*03:02 27 (5.9) 46 (5.4) 0.892 1.035 (0.633, 1.693)
DQB1*03:03 77 (16.7) 126 (14.7) 0.579 1.093 (0.798, 1.499)
DQB1*05:02 38 (8.3) 113 (13.2) 0.002 (0.016) 0.547 (0.370, 0.809)
DQB1*06:01 41 (8.9) 84 (9.8) 0.394 0.842 (0.567, 1.251)
DQB1*06:02 22 (4.8) 52 (6.1) 0.227 0.729 (0.436, 1.220)
DRB1*03:01 31 (6.7) 60 (7.0) 0.626 0.893 (0.565, 1.410)
DRB1*04:05 16 (3.5) 52 (6.1) 0.022 (0.176) 0.514 (0.288, 0.916)
DRB1*07:01 35 (7.6) 47 (5.5) 0.214 1.338 (0.844, 2.120)
DRB1*08:03 23 (5.0) 44 (5.1) 0.715 0.907 (0.537, 1.531)
DRB1*09:01 77 (16.7) 117 (13.6) 0.281 1.197 (0.863, 1.659)
DRB1*11:01 44 (9.5) 45 (5.2) 0.007 (0.056) 1.820 (1.172, 2.826)
DRB1*12:02 56 (12.1) 96 (11.2) 0.9 1.024 (0.713, 1.470)
DRB1*15:01 43 (9.3) 107 (12.5) 0.031 (0.248) 0.657 (0.448, 0.964)
Open in a new tab

Alleles with >5% frequencies are shown at the 4-digit level and analyzed; Pc, Corrected P value for multiple comparisons by Bonferroni correction. Alleles with statistical significance after Bonferroni correction are indicated in bold.

HLA alleles associate with HCV spontaneous clearance when the effect of IL28B SNP is considered

The association of IL28B SNPs with spontaneous and treatment induced HCV clearance has been extensively studied8,9,11. In order to address whether the associations of HLA alleles with HCV clearance were IL28B-independent, we genotyped two SNPs related to the IL28B gene, rs8099917 and rs12979860. The frequency of rs8099917-T allele, which favored HCV clearance, was greater than 90% in both groups, and it was significantly higher in the HCV clearance group compared to the persistent infection group (Table 4, 97.6% vs. 91.3%, P = 7.97E-6 in Chi-square test). The majority of the donors carried the favorable TT genotype, which was more frequent in the spontaneous clearance group than in the persistent infection group (95.7% vs. 82.5%, P = 1.50E-6 in Chi-square test). Similar results were obtained for rs12979860 (Table S3, P = 1.04E-5 and P = 2.03E-6 in Chi-square test for allele and genotype, respectively). Rs8099917 was in strong linkage disequilibrium with rs12979860 (Spearman’s rho = 0.993, data not shown).

Table 4. Association of IL28B (rs8099917) with HCV infection outcome in Chinese population.

rs8099917 Spontaneous clearance n (%) Persistent infection n (%) P OR (95%C.I.)
Allele
 T 451 (97.6) 783 (91.3) 7.97E-6 3.927 (2.064, 7.473)
 G 11 (2.4) 75 (8.7)
Genotype
 TT 221 (95.7) 354 (82.5) 1.50E-6 (TT vs. TG + GG) 4.682 (2.370, 9.250)
 TG 9 (3.9) 75 (17.5)
 GG 1 (0.4) 0 (0)
Open in a new tab

To address the impact of IL28B on the association of HLA and HCV clearance, we stratified the study subjects according to their rs8099917 genotype and re-analyzed the six specific HLA alleles described above, i.e., A*02:01, DQB1*03:01, DQB1*05:02, DRB1*04:05, DRB1*11:01 and DRB1*15:01. As shown in Table S4, among donors who carried the protective IL28B TT genotype, HLA-A*02:01, DQB1*03:01 and DRB1*11:01 (OR = 1.673, P = 0.016; OR = 1.555, P = 0.002 and OR = 1.851, P = 0.007, respectively) were more frequent in the spontaneous clearance group, while DQB1*05:02 and DRB1*04:05 (OR = 0.582, P = 0.008 and OR = 0.516, P = 0.023, respectively) were more prevalent in the persistent infection group. DRB1*15:01 appeared to be less frequent in the spontaneous clearance group than in the persistence group (9.3% vs. 12.6%), but the difference was not statistically significant (P = 0.086). No significant association was found in the IL28B deleterious genotype (TG + GG), which was probably due to the small sample size in the clearance group (n = 10). These results suggested an IL28B-independent association between HLA class I and class II alleles and HCV spontaneous clearance.

The association of HLA-A*02:01 and DRB1*11:01 with HCV spontaneous clearance were independent of gender, age and IL28B

It has been established that subjects who are females and younger are more likely to clear HCV spontaneously6,15,31. In this study, the male/female ratio and age were also significantly different between the spontaneous clearance group and the persistent infection group (Table 1). We then investigated whether the associations of these HLA alleles and HCV spontaneous clearance were independent of age, gender and IL28B SNP. A multivariate logistic regression analysis incorporating potential confounding factors including age, gender and IL28B was done and the results were shown in Table 5. The following variables were found independently associated with HCV clearance: gender (OR = 0.405, 95% CI = 0.310–0.531, P = 5.05E-11), age (OR = 1.035, 95% CI = 1.021–1.048, P = 3.02E-7), rs8099917 (OR = 3.842, 95% CI = 1.993–7.405, P = 5.82E-5), HLA-A*02:01 (OR = 1.798, 95% CI = 1.169–2.766, P = 0.008) and DRB1*11:01 (OR = 1.921, 95% CI = 1.223–3.017, P = 0.005). In contrast, DQB1*03:01 (P = 0.244), DQB1*05:02 (P = 0.051), DRB1*04:05 (P = 0.069) and DRB1*15:01 (P = 0.305), although distributed differently in the two groups, were not independently associated with HCV clearance. Taken together, our results suggested that HLA-A*02:01 and DRB1*11:01 associated with HCV clearance independent of age, gender and IL28B.

Table 5. Logistic regression analysis of variables associated with HCV spontaneous clearance.

Variables OR (95% CI) p value
Age 1.035 (1.021, 1.048) 3.02E-7
Gender (M/F) 0.405 (0.310, 0.531) 5.05E-11
Rs8099917 (T/G) 3.842 (1.993, 7.405) 5.82E-5
HLA-A*02:01 1.798 (1.169, 2.766) 0.008
HLA-DQB1*03:01 Not enter the equation 0.244
HLA-DQB1*05:02 Not enter the equation 0.051
HLA-DRB1*04:05 Not enter the equation 0.069
HLA-DRB1*11:01 1.921 (1.223, 3.017) 0.005
HLA-DRB1*15:01 Not enter the equation 0.305
Open in a new tab

Prediction of HCV spontaneous clearance by HLA and IL28B

Since there is a high prevalence of an IL28B favorable allele/genotype (Table 4) but a relatively low spontaneous HCV clearance level in the Chinese population17, the associations of IL28B and other host factors with viral clearance should be evaluated. We evaluated the sensitivity and positive predictive value (PPV) of IL28B and the two HLA alleles described above (HLA-A*02:01 and DRB1*11:01) with HCV clearance. As shown in Table S5, after adjusting for age and gender, the sensitivity of IL28B on HCV clearance was 22.9%, in comparison with 26.0% for the HLA alleles. The PPV was comparable for IL28B and HLA alleles (57.0% and 55.8%, respectively). When considering IL28B SNP and HLA-A*02:01 and DRB1*11:01 together, a slightly additive effect was observed (sensitivity = 28.1%, and PPV = 57.8%). In summary, considering both the IL28B genotype and HLA genes together can improve the prediction of the probability of HCV spontaneous clearance.

Discussion

In a previous study we reported the association of HLA with HCV infection28. In this study, the parts of HLA-A, B and DRB1 genotypes obtained previously from blood donors28 were used as persistent HCV infection group in comparison with spontaneous HCV clearance. We aimed to examine the association of HLA class I and class II alleles with HCV spontaneous clearance in the Chinese population. In particular, we aimed to evaluate the association of HLA alleles in the context of IL28B polymorphisms, which has been shown to be strongly correlated with HCV clearance. To our knowledge, the present study is the first of its kind among the Chinese population. The study subjects had experienced an asymptomatic HCV infection at the time of enrollment and were treatment naïve, thus making it ideal for studying of the HCV natural history.

In our initial analysis, higher percentage of female presented in the HCV spontaneous clearance group compared with the persistent infection group (34.2% vs.17.2%, Table 1), indicating that female gender were more likely to clear HCV than male. Actually, the spontaneous clearance rate of HCV for female was higher than male (26.8% vs. 12.7%, Table S1). Our results demonstrated that gender influenced on HCV clearance, which was in line with that previously described in other studies5,6,7. Besides, subjects in the clearance group tended to be younger than those in the persistence group (Table 1), which was also in accordance with previous reports5,6,7. Therefore, these two host factors must be considered when assessing the association of HLA and HCV clearance.

We applied high resolution HLA genotyping to assess and compare their frequencies between the spontaneous clearance group and the persistent infection group. Six alleles (A*02:01, DQB1*03:01, DQB1*05:02, DRB1*04:05, DRB1*11:01 and DRB1*15:01) were distributed differently between the two groups, but only A*02:01 and DQB1*05:02 reached statistical significance after Bonferroni correction (Pc < 0.05), which was calculated by dividing the P value by the number of alleles with frequency >5%. However, this association considered only the frequency of the HLA alleles. The confounding effects of other potential factors remained unknown. It has been well established that the IL28B polymorphism is strongly associated with the HCV natural history and treatment outcome5,8,9,11. However, only a few studies have considered the effect of IL28B in assessing the association of HLA and HCV clearance13. In addition, as previously described, confounding factors including gender and age should be included to determine the association of HLA and HCV clearance. Therefore, multivariate logistic regression was performed using the age, gender, IL28B and HLA alleles with P < 0.05 by univariate analysis without correction (A*02:01, DQB1*03:01, DQB1*05:02, DRB1*04:05, DRB1*11:01, DRB1*15:01) as candidates. Multivariate logistic regression analysis supported the association of A*02:01 and DRB1*11:01 with HCV clearance, independent of IL28B, gender or age.

A number of studies have shown associations of HLA class I and class II alleles with HCV natural history or treatment outcome. We compared our findings with that of other studies (Table 6). HLA-A*02 is one of the most frequent HLA alleles in the population of European/Caucasian descent as well as in Chinese and Japanese32,33. This allele appeared to be associated with protection against chronic HCV since it was more prevalent among the healthy than the HCV-infected population34. HLA-A*02 may also be an independent predictor for an effective immune responses to interferon and ribavirin therapy in Chinese subjects who were infected with chronic hepatitis C33. Interestingly, A*02 seemed to be associated with lower clearance of HCV among Caucasians and higher clearance of HCV among non-Caucasians27. Here we reported the first study in which A*02:01 is associated with HCV spontaneous clearance in the Chinese population, and proposed the inclusion of this allele in assessing the risk of developing chronic hepatitis C in subjects of different ethnical origins. It should be noted that the current study applied high resolution 4-digit genotyping, which provided more accurate and robust data compared to the traditional 2-digit level that was commonly used in previous reports23,24,25,33. Our high resolution HLA genotyping results showed that A*02:01, rather than A*02:03 or A*02:07, was significantly associated with HCV clearance (Table 2). Such specific association would be missed if only 2-digit HLA genotyping was used.

Table 6. Summary of HLA alleles with HCV clearance or persistence in published reports and this study.

Associated HLA allele Association with HCV population (clearance or SVR/persistence or NR, if not specified) Study
A*02 Persistence in Caucasian; spontaneous clearance in non-Caucasians USA (49/56) 27
  SVR Chinese (144 A*02 positive/149 A*02 negative patients) 33
  Protective USA (11,728 HCV uninfected/5901 HCV infected) 34
A*02:01 Spontaneous clearance* Chinese (231/429) This study
A*02:03 No association Chinese (231/429) This study
A*02:07 No association Chinese (231/429) This study
B*57 Spontaneous clearance USA (231/444) 23
  Spontaneous clearance USA(136/622) 25
  Spontaneous clearance USA (66/280) 29
  Spontaneous clearance West Africa (35/37) 30
  No association USA (79/200) 35
  No association Chinese (231/429) This study
DQB1*03 Spontaneous clearance USA (49/56) 27
  Protective USA (11,728 HCV uninfected/5901 HCV infected) 34
  Protective Japan (2,963 healthy controls/481 chronic HCV infected) 42
DQB1*03:01 Spontaneous clearance USA (200/374) 26
  Spontaneous clearance Italy (49/68) 41
  Spontaneous clearance Iran (54/63) 38
  Spontaneous clearance Chinese (432/686) 43
  SVR Chinese (156/87) 43
  SVR Pakistan (150/54) 36
  Clearance Meta-analysis 37
  Clearance Meta-analysis 7
DQB1*03:01 No association Chinese (231/429) This study
DQB1*05 Spontaneous clearance USA (49/56) 27
DQB1*05:01 Spontaneous clearance USA (200/374) 26
DQB1*05:02 Clearance Italy (30 exposed but uninfected/116 HCV infected) 45
DQB1*05:02 No association Chinese (231/429) This study
DRB1*11 Clearance Meta-analysis 7
  Spontaneous clearance Iran (54/63) 38
  SVR Pakistan (150/54) 36
  Protective USA (11,728 HCV uninfected/5901 HCV infected) 34
  Protective Italy (70 HCV uninfected/73 HCV seropositive) 39
DRB1*11:01 Spontaneous clearance UK (85/170) 40
  Clearance Meta-analysis 37
DRB1*11:01 Spontaneous clearance Chinese (231/429) This study
DRB1*15 Spontaneous clearance Ireland (86/141) 24
  Spontaneous clearance Germany (21/49) 46
  Persistence Tunisia (24/75) 47
DRB1*15:01 No association Chinese (231/429) This study
Open in a new tab

*The significance of the association in this study was determined by the results of logistic regression analysis.

Several studies had demonstrated that HLA-B*57 is associated with HCV spontaneous clearance23,25,29,30,35. The carriage of B*57 and the recognition of B*57-restricted T-cell responses have been associated with HCV clearance29. However, this association was not found in this study, probably because of the very low prevalence of the B*57 allele in the Chinese population. It was found in only 0.4% and 0.6% of the two groups in this study, whereas it was present in 10–15% of the allele in American or African populations23,25.

The protective role of HLA-DRB1*117,34,36,37,38,39,40 and DQB1*037,26,27,34,36,37,38,41,42,43 with HCV clearance has been consistently reported across diverse populations. Our results supported the association of DRB1*11:01 with HCV spontaneous clearance (Table 5). However, although DQB1*03:01 seemed more prevalent in subjects who cleared HCV than those with persistent infection, the association was marginal (Table 3) and not independent of IL28B, gender and age (Table 5). The discrepant results on DQB1*03:01 between published data and this study can not be simply explained by the difference of the studied population. Actually, we observed that DQB1*03:01 associated with IL28B, A*02:01 and DRB1*11:01 (r = 0.08, P = 0.004; r = 0.093, P = 0.001 and r = 0.304, P = 1.38E-29, respectively, data not shown). In our stratified analysis, the association of DQB1*03:01 and HCV clearance was stronger in subjects carried IL28B TT genotype (Table S3) or A*:02:01 (data not shown), indicating that DQB1*03:01 was associated with HCV clearance when confounding factors were considered. In addition. DRB1*11:01 and DQB1*03:01 are well known to be highly associated because of linkage disequilibrium44 and this association was verified in our data (D’ = 0.983, P = 1E-37, data not shown). Therefore, our logistic regression model incorporating DRB1*11:01 excluded DQB1*03:01 as associated with HCV clearance. Taken together, our results verified the association of DRB1*11:01 on HCV spontaneous clearance in the Chinese population, and we speculated that the association of DQB1*03:01 with HCV clearance may be masked by IL28B, HLA-A*02:01 and DRB1*11:01.

Our results also suggested that subjects carrying HLA-DQB1*05:02 were at greater risk of developing chronic hepatitis C (Table 3). This allele was marginally associated with failure of HCV resolution (P = 0.051, Table 5). This contrasted with the study of Congia et al., which reported an association between DQB1*05:02 and HCV clearance in the presence of DRB1*16:0145. It should be pointed out that Congia’s study subjects were of different ethnic origin compared to ours, and the sample size in our study was larger than Congia’s study. In addition, HLA-DQB1*0527 and DQB1*05:0126 were also reported to be associated with the spontaneous clearance of HCV, which disagreed with our results. We suspect that the slight difference on the studied alleles (DQB1*05, 05:01 and 05:02) and the subjects of different ethnicity may account for the discordant results. Further investigation is required to determine the role of DQB1*05, 05:01 or 05:02 on HCV outcome in diverse ethnical groups.

The association of DRB1*15 with HCV spontaneous clearance is unclear. While this allele was not associated with HCV clearance in this study, Lechmann et al. reported an increased frequency of DRB1*15 in German HCV patients with resolution of HCV infection46; this was supported by McKiernan’s study of a group of Irish women who infected HCV from a single source24. However, the study conducted by Ksiaa et al. in Tunisia found that DRB1*15 occurred more often in chronic HCV infected subjects compared with those with viral clearance47. The role of DRB1*15 in HCV outcome is still elusive and seems to be population specific, which requires further study to determine.

Despite a strong correlation of IL28B SNP with spontaneous and treatment induced HCV clearance, IL28B SNP can only predict about 15% of the spontaneous clearance11 and two-thirds of the sustained virological responses to antiviral therapy among HCV infected patients10. In the Chinese population, the favorable IL28B allele/genotype did not appear to be a good predictor for HCV spontaneous clearance, because its frequency was over 90% in both subjects who had cleared HCV and those with persistent infections (Table 4 and ref. 16). The association of rs8099917 and HCV clearance was more apparent among the minority of subjects with the unfavorable IL28B genotype. Subjects with this IL28B genotype were 3.6-fold more likely to have persistent infection than spontaneous clearance (i.e. 8.7% vs. 2.4%, Table 4). It is plausible that factors other than IL28B SNP are involved in HCV clearance in the Chinese population. To explore this possibility, we assessed the prediction of HCV spontaneous clearance by optimizing the multivariate model with rs8099917 and HLA alleles (A*02:01 and DRB1*11:01). Both IL28B and HLA alleles had comparable predictive values, while a slightly additive effect was observed when both IL28B and HLAs were considered (Table S4). Our results are similar to those reported by Fitzmaurice et al. in Irish women13. Taken together, the independent associations of IL28B SNP and HLA with HCV clearance supported the importance of the integration of host innate and adaptive immune genes on the control of HCV viremia.

In conclusion, our results found that in the Chinese population, HLA-A*02:01 and DRB1*11:01 were individually associated with HCV spontaneous clearance, even after the effect of IL28B was considered. These two HLA alleles, together with IL28B, should be considered in the prediction of the spontaneous HCV clearance.

Methods

Study subjects

All the study subjects were voluntary blood donors who passed pre-donation questionnaire and donated their blood at Guangzhou Blood Center between July 2009 and March 2015. Before their blood donation, all individuals were requested to complete a blood donation health consent form for the study participation. Blood samples collected at donation were used to test HCV and other pathogens (see “detection of HCV infection” section below). A follow-up examination for the HCV seropositive donors was performed 6 months after their blood donation. Physicians interviewed the participants to assure their understanding of the informed consent for both enrollment and follow-up examination. Donors who were anti-HCV and HCV RNA positive at both enrollment and follow-up examination represented the HCV persistent infected group, while those who with undetectable HCV RNA but positive for anti-HCV at both tests represented the HCV spontaneous clearance group. All the subjects with HCV clearance (n = 231) were enrolled, while 429 subjects of the persistent infection group were sampled using systematic random sampling method from 1262 persistent infected blood donors who were recruited during the same period. This study strictly followed the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Medical Ethics Committee of Guangzhou Blood Center.

Detection of HCV infection

Screening of HBV, HCV, human immunodeficiency virus (HIV) and Treponema pallidum (TP) and follow-up examination was done as previously described28. Briefly, two independent enzyme-linked immunosorbent (EIA) kits were applied to detect anti-HCV (Kehua HCV EIA assay, Kehua Biotech Co. Ltd., Shanghai, China and Abbott HCV EIA 2.0, Abbott Laboratories, Chicago, IL, USA). HBV, HIV and TP were also detected by two EIA assays. HBV DNA, HCV RNA and HIV RNA were detected using nucleic acid testing (NAT, Procleix Ultrio Assay; Gen-Probe, San Diego, CA, USA) according to the manufacturers’ instruction. All the enrolled blood donors were positive for anti-HCV and negative for anti-HIV, HBV surface antigen (HBsAg), anti-TP antibody, as well as HBV and HIV nucleic acids. EIA-reactive and HCV RNA negative specimens were subsequently tested by a third-generation recombinant immunoblot assays (RIBA. HCV Blot 3.0, MP Diagnostics, Singapore) to determine the presence of anti-HCV antibody. Donors with HCV RNA negative and RIBA positive in donation and follow up examination were assigned to the spontaneous clearance group, while those who had detectable HCV RNA in the two examinations were assigned to the persistent infection group.

IL28B genotyping

Two IL28B SNPs, rs8099917 and rs12979860, were genotyped by PCR and Sanger sequencing. First, genomic DNAs were extracted from whole blood samples using QuickGene-610L system (Fujifilm, Tokyo, Japan) following manufacturers’ instruction. The DNA fragments containing rs8099917 or rs12979860 were amplified using GoTaq Colorless Master Mix (Promega, Madison, WI, USA) with the presence of 0.5 μM primers. The primer sequences were designed as following: (5′-3′): rs8099917-F, CCACTTCTGGAACAAATCGTCCC; rs8099917-R, TCAACCCCACCTCAAATTATCCT; rs12979860-F, GGACGAGAGGGCGTTAGAG; rs12979860-R, GGCTCAGGGTCAATCACAG. The length of amplicons containing rs8099917 and rs12979860 were 294 and 309 bp, respectively. The amplicons were subsequently applied to Sanger sequencing in both directions by ABI 3730 DNA Sequencer (Applied Biosystems, Foster City, CA, USA). The SNP genotype was determined by assembling the obtained sequences using SeqMan software (DNAStar, Inc. Madison, WI, USA).

HLA genotyping

HLA-A, B, C, DPB1, DQB1 and DRB1 alleles were assigned according to the HLA sequencing based typing methodology as previously described28. In brief, the amplicons containing HLA fragments were purified using ExoSAP-IT (Atria Genetics) and sequenced in both directions. The HLA alleles were assigned at a 4-digit level using the ASSIGN 3.5 software (Conexio Genomics, Perth, WA, Australia). Any ambiguous results were applied to additional exon sequencing48. The HLA-A, B and DRB1 genotype for some of the persistent infection donors were extracted from our previous report28, while the others were first reported in this study.

Statistical analysis

The frequency of IL28B SNP and HLA alleles was calculated by direct counting from the sequencing results. Possible age difference between the HCV spontaneous clearance group versus the persistent infection group was examined by the T-test. Individual association of gender, ethnicity, IL28B SNP and HLA alleles with HCV clearance was examined by the Chi-square test or Fisher’s exact test when Chi-square test can not applied. Association strength was calculated by OR with 95% CI and statistical P-value. The Bonferroni correction was applied for multiple comparisons. Statistically significant association was indicated when the P-value was less than 0.05. Multivariate logistic regression using forward conditional stepwise method was applied to identify independent factors associated with HCV clearance. Statistical analyses were performed in SPSS version 16.0 (SPSS Inc, Chicago, IL, USA).

Additional Information

How to cite this article: Huang, J. et al. The Associations of HLA-A*02:01 and DRB1*11:01 with Hepatitis C Virus Spontaneous Clearance Are Independent of IL28B in the Chinese Population. Sci. Rep. 6, 31485; doi: 10.1038/srep31485 (2016).

Supplementary Material

Supplementary Information
srep31485-s1.pdf (493.5KB, pdf)

Acknowledgments

We are grateful to Dr. Xin Ye, Dr. Wenjie Xia and Dr. Xiuzhang Xu at Guangzhou Blood Center for the assistance of high-resolution HLA genotyping. This research was supported by the grants from National Natural Science Foundation of China (No. 81273145 and No. 81402733), the Natural Science Foundation of Guangdong Province (No. 2014A030311005) and Science and Technology Project of Guangzhou city (No. 201509010009). The funding agencies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Footnotes

Author Contributions J.H. drafted the main manuscript. R.X., C.L. and Y.F. contributed to study design. R.X., M.W., Q.L., H.X., X.T. and Z.S. contributed to donor recruitment and data collection. J.H. and K.H. performed statistical analysis and the interpretation of the data. C.L., M.Z., K.N. and Y.F. revised the manuscript. X.R. and Y.F. conceived the study and approved the manuscript. All authors reviewed and approved the final version of the manuscript.

References

  1. Hoofnagle J. H. Course and outcome of hepatitis C. Hepatology 36, S21–29, 10.1053/jhep.2002.36227 (2002). [DOI] [PubMed] [Google Scholar]
  2. Mohd Hanafiah K., Groeger J., Flaxman A. D. & Wiersma S. T. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57, 1333–1342, 10.1002/hep.26141 (2013). [DOI] [PubMed] [Google Scholar]
  3. National Health and Family Planning Commission of the People’s Republic of China. The epidemic situation of infectious diseases, < http://www.nhfpc.gov.cn/zhuzhan/yqxx/lists.shtml> (Accessed in June 12th 2016).
  4. Thomas D. L. Global control of hepatitis C: where challenge meets opportunity. Nature medicine 19, 850–858, 10.1038/nm.3184 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Grebely J. et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 59, 109–120, 10.1002/hep.26639 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Shah D. P., Grimes C. Z., Brown E. & Hwang L. Y. Demographics, socio-behavioral factors, and drug use patterns: what matters in spontaneous HCV clearance? Journal of medical virology 84, 235–241, 10.1002/jmv.22271 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Yee L. J. Host genetic determinants in hepatitis C virus infection. Genes and immunity 5, 237–245, 10.1038/sj.gene.6364090 (2004). [DOI] [PubMed] [Google Scholar]
  8. Thomas D. L. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461, 798–801, 10.1038/nature08463 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ge D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399–401, 10.1038/nature08309 (2009). [DOI] [PubMed] [Google Scholar]
  10. Kelly C., Klenerman P. & Barnes E. Interferon lambdas: the next cytokine storm. Gut 60, 1284–1293, 10.1136/gut.2010.222976 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Duggal P. et al. Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Annals of internal medicine 158, 235–245, 10.7326/0003-4819-158-4-201302190-00003 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Liver E. A. f. S. o. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. Journal of hepatology 60, 392–420, 10.1016/j.jhep.2013.11.003 (2014). [DOI] [PubMed] [Google Scholar]
  13. Fitzmaurice K. et al. Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection. Gut 64, 813–819, 10.1136/gutjnl-2013-306287 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Sarkar M. et al. Racial/ethnic differences in spontaneous HCV clearance in HIV infected and uninfected women. Digestive diseases and sciences 58, 1341–1348, 10.1007/s10620-012-2486-8 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Thomas D. L. et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. Jama 284, 450–456 (2000). [DOI] [PubMed] [Google Scholar]
  16. Shi X. et al. IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population. PloS one 7, e37054, 10.1371/journal.pone.0037054 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Rao H. Y. et al. Outcome of hepatitis C virus infection in Chinese paid plasma donors: a 12-19-year cohort study. Journal of gastroenterology and hepatology 27, 526–532, 10.1111/j.1440-1746.2011.06880.x (2012). [DOI] [PubMed] [Google Scholar]
  18. Thimme R. et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. The Journal of experimental medicine 194, 1395–1406 (2001). [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Dazert E. et al. Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response. The Journal of clinical investigation 119, 376–386, 10.1172/JCI36587 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Klenerman P. & Hill A. T cells and viral persistence: lessons from diverse infections. Nature immunology 6, 873–879, 10.1038/ni1241 (2005). [DOI] [PubMed] [Google Scholar]
  21. Lechner F. et al. Analysis of successful immune responses in persons infected with hepatitis C virus. The Journal of experimental medicine 191, 1499–1512 (2000). [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Penna A. et al. Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology 45, 588–601, 10.1002/hep.21541 (2007). [DOI] [PubMed] [Google Scholar]
  23. Thio C. L. et al. HLA-Cw*04 and hepatitis C virus persistence. Journal of virology 76, 4792–4797 (2002). [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. McKiernan S. M. et al. Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. Hepatology 40, 108–114, 10.1002/hep.20261 (2004). [DOI] [PubMed] [Google Scholar]
  25. Kuniholm M. H. et al. Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia. Hepatology 51, 1514–1522, 10.1002/hep.23515 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Thio C. L. et al. Racial differences in HLA class II associations with hepatitis C virus outcomes. The Journal of infectious diseases 184, 16–21, 10.1086/321005 (2001). [DOI] [PubMed] [Google Scholar]
  27. Wang J. H. et al. Ethnic and geographical differences in HLA associations with the outcome of hepatitis C virus infection. Virology journal 6, 46, 10.1186/1743-422X-6-46 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Xiong H. et al. HLA-B alleles B*15:01 and B*15:02: opposite association with hepatitis C virus infection in Chinese voluntary blood donors. Intervirology 58, 80–87, 10.1159/000369209 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Kim A. Y. et al. Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes. Gastroenterology 140, 686–696 e681, 10.1053/j.gastro.2010.09.042 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Chuang W. C. et al. Protective effect of HLA-B57 on HCV genotype 2 infection in a West African population. Journal of medical virology 79, 724–733, 10.1002/jmv.20848 (2007). [DOI] [PubMed] [Google Scholar]
  31. Alric L. et al. Study of host- and virus-related factors associated with spontaneous hepatitis C virus clearance. Tissue antigens 56, 154–158 (2000). [DOI] [PubMed] [Google Scholar]
  32. Gonzalez-Galarza F. F. et al. Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic acids research 43, D784–788, 10.1093/nar/gku1166 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Wang M. et al. The host HLA-A*02 allele is associated with the response to pegylated interferon and ribavirin in patients with chronic hepatitis C virus infection. Archives of virology 160, 1043–1054, 10.1007/s00705-015-2361-y (2015). [DOI] [PubMed] [Google Scholar]
  34. Hraber P., Kuiken C. & Yusim K. Evidence for human leukocyte antigen heterozygote advantage against hepatitis C virus infection. Hepatology 46, 1713–1721, 10.1002/hep.21889 (2007). [DOI] [PubMed] [Google Scholar]
  35. Asher A. K. et al. Human leukocyte antigen B*57 does not fully explain hepatitis C clearance in HIV controllers. AIDS 27, 2691–2696, 10.1097/01.aids.0000433242.86362.21 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Ali L. et al. Patient HLA-DRB1* and -DQB1* allele and haplotype association with hepatitis C virus persistence and clearance. The Journal of general virology 91, 1931–1938, 10.1099/vir.0.018119-0 (2010). [DOI] [PubMed] [Google Scholar]
  37. Hong X. et al. Human leukocyte antigen class II DQB1*0301, DRB1*1101 alleles and spontaneous clearance of hepatitis C virus infection: a meta-analysis. World journal of gastroenterology 11, 7302–7307 (2005). [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Samimi-Rad K. et al. Association of HLA class II alleles with hepatitis C virus clearance and persistence in thalassemia patients from Iran. Journal of medical virology 87, 1565–1572, 10.1002/jmv.24211 (2015). [DOI] [PubMed] [Google Scholar]
  39. Scotto G. et al. Association between HLA class II antigens and hepatitis C virus infection. Journal of biological regulators and homeostatic agents 17, 316–321 (2003). [PubMed] [Google Scholar]
  40. Thursz M., Yallop R., Goldin R., Trepo C. & Thomas H. C. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet 354, 2119–2124 (1999). [DOI] [PubMed] [Google Scholar]
  41. Mangia A. et al. IL28B CC-genotype association with HLA-DQB1*0301 allele increases the prediction of spontaneous HCV RNA clearance in thalassaemic HCV-infected patients. Antiviral therapy 16, 1309–1316, 10.3851/IMP1913 (2011). [DOI] [PubMed] [Google Scholar]
  42. Miki D. et al. HLA-DQB1*03 confers susceptibility to chronic hepatitis C in Japanese: a genome-wide association study. PloS one 8, e84226, 10.1371/journal.pone.0084226 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Xu Y. et al. A novel polymorphism near HLA class II region is associated with spontaneous clearance of HCV and response to interferon treatment in Chinese patients. Journal of human genetics 61, 301–305, 10.1038/jhg.2015.145 (2016). [DOI] [PubMed] [Google Scholar]
  44. Maiers M., Gragert L. & Klitz W. High-resolution HLA alleles and haplotypes in the United States population. Human immunology 68, 779–788, 10.1016/j.humimm.2007.04.005 (2007). [DOI] [PubMed] [Google Scholar]
  45. Congia M. et al. HLA class II genes in chronic hepatitis C virus-infection and associated immunological disorders. Hepatology 24, 1338–1341, 10.1002/hep.510240603 (1996). [DOI] [PubMed] [Google Scholar]
  46. Lechmann M. et al. Increased frequency of the HLA-DR15 (B1*15011) allele in German patients with self-limited hepatitis C virus infection. European journal of clinical investigation 29, 337–343 (1999). [DOI] [PubMed] [Google Scholar]
  47. Ksiaa L. et al. Clearance and persistence of hepatitis C virus in a Tunisian population: association with HLA class I and class II. Viral immunology 20, 312–319, 10.1089/vim.2006.0060 (2007). [DOI] [PubMed] [Google Scholar]
  48. Deng Z. et al. HLA-C polymorphisms and PCR dropout in exons 2 and 3 of the Cw*0706 allele in sequence-based typing for unrelated Chinese marrow donors. Human immunology 71, 577–581, 10.1016/j.humimm.2010.03.001 (2010). [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Information
srep31485-s1.pdf (493.5KB, pdf)

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES